Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
domvanalimab + zimberelimab + APX005M
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This investigational regimen is a combination of three novel immune-oncology agents: domvanalimab, zimberelimab, and APX005M, used in clinical trials for advanced cancers such as non-small cell lung cancer and gastrointestinal malignancies. - **Domvanalimab** is an Fc-silent monoclonal antibody targeting TIGIT (T-cell immunoreceptor with Ig and ITIM domains), aiming to block the TIGIT immune checkpoint, thus enhancing anti-tumor immunity by preventing cancer cells from inhibiting immune cell attack[1][7]. - **Zimberelimab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), designed to block the PD-1 checkpoint pathway and reactivate T-cell-mediated anti-tumor activity[5][6]. - **APX005M** (sabatolimab) is a CD40 agonist monoclonal antibody intended to further stimulate immune activation via CD40, a key costimulatory protein on antigen-presenting cells (APCs), thereby enhancing T cell priming, dendritic cell activation, and overall immune response against tumors.
- Other names
- domvanalimab + zimberelimab + APX005M
02
Targets
CD40 (Cluster of differentiation 40 receptor)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on domvanalimab + zimberelimab + APX005M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on domvanalimab + zimberelimab + APX005M.